SCHEMBL7716801

SCHEMBL7716801

CC(=O)NS(=O)(=O)c1ccc(F)c(F)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.60
TDP1 Q9NUW8 2/20 0.56
TSHR P16473 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
DHFR P00374 1/20 0.56
POLB P06746 1/20 0.55
KMT2A Q03164 3/20 0.52
MEN1 O00255 1/20 0.52
SLC1A3 P43003 1/20 0.50
SLC1A2 P43004 1/20 0.50
SLC1A1 P43005 1/20 0.50
ALDH1A1 P00352 2/20 0.49
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
LMNA P02545 1/20 0.47
PTGS2 P35354 1/20 0.46
FLT1 P17948 1/20 0.46
FLT4 P35916 1/20 0.46
KDR P35968 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19629758 0.83 KMT2A (0.57) PKMTDP1TSHRSMN1; SMN2KMT2A
SCHEMBL19627389 0.83 KMT2A (0.50) PKMTDP1TSHRKMT2AMEN1
SCHEMBL19634273 0.82 KMT2A (0.52) TDP1TSHRSMN1; SMN2KMT2AMEN1
SCHEMBL8277082 0.81 ALDH1A1 (0.59) TDP1TSHRKMT2AMEN1SLC1A3
SCHEMBL7714429 0.79 POLB (0.81) PKMTDP1TSHRSMN1; SMN2DHFR
SCHEMBL19627384 0.79 KMT2A (0.53) TDP1TSHRKMT2AMEN1SLC1A3
SCHEMBL6849915 0.78 CA1 (0.58) TDP1KMT2AMEN1SLC1A3SLC1A2
SCHEMBL13649414 0.77 PKM (0.54) PKMTDP1TSHRSMN1; SMN2DHFR
SCHEMBL425487 0.77 KMT2A (0.58) TDP1SMN1; SMN2KMT2AMEN1SLC1A3
SCHEMBL7402304 0.76 TSHR (0.67) PKMTDP1TSHRSMN1; SMN2DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170333399-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-11-23 US disclosed
US-20170334894-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-11-23 US disclosed
WO-2011133600-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-10-27 WO disclosed
WO-2010123822-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334894-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof SLC10A1, FXR1, NR1H4 PKM 1995/4885TDP1 3945/4885TSHR 737/4885
US-20170333399-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof SLC10A1, FXR1, SLC10A2 PKM 2305/4885TDP1 3899/4885TSHR 805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.